HK Stock Market Move | ZYLOXTB(02190) rose by over 5% after the profit excitement, with the expected net profit for the year 25 increasing by nearly 1.4 times year-on-year. The key breakthrough in the internationalization strategy has been achieved.

ZYLOXTB(02190) rose by over 5% after the announcement, with a 4.06% increase as of the time of writing, reaching HK$24.46, with a trading volume of HK$43.55 million. On the news front, on January 29th, ZYLOXTB released a positive profit forecast for the full year of 2025. The company expects a net profit of over RMB 240 million for the full year of 2025, a significant increase of approximately 139.4% compared to the same period last year; and operating income of over RMB 1.05 billion, a year-on-year growth of approximately 34.6%. ZYLOXTB stated that the company's performance in 2025 is outstanding, mainly benefiting from strong growth in core product sales, accelerated development of overseas business, and continuous optimization of operational efficiency. During the reporting period, sales revenue of products such as Tongqiao Qilin blood flow guiding device, neurovascular guidewires, UltraFree drug-eluting PTA balloon dilatation catheters, and ZYLOX Swan intravenous radiofrequency closure catheters all achieved rapid growth. In terms of international business, the company's overseas market sales revenue grew by over 100% year-on-year, with penetration rates in key countries such as Germany, France, and Italy continuing to rise. At the same time, the company's internationalization strategy achieved crucial breakthroughs, with the expansion of overseas markets accelerating comprehensively. By the end of 2025, the company's sales channels covered 83 countries and regions worldwide, and strategic partnerships were established with over 80 overseas partners. In January 2026, the company announced the strategic acquisition of Germany's Optimed company, further expanding its layout in European and global markets, accelerating the promotion and implementation of innovative products in international markets; and relying on the synergies between the two major production bases in China and Germany, continuously enhancing global operational and delivery capabilities.